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Abstract
Both somatic copy number alterations (CNAs) and germline copy number variants
(CNVs) that are prevalent in healthy individuals can appear as recurrent changes in
comparative genomic hybridization (CGH) analyses of tumors. In order to iden-
tify important cancer genes CNAs and CNVs must be distinguished. Although
the Database of Genomic Variants (Iafrate et al., 2004) contains a list of all known
CNVs, there is no standard methodology to use the database effectively.
We develop a prediction model that distinguishes CNVs from CNAs based on
the information contained in the Database and several other variables, including
potential CNV’s length, height, closeness to a telomere or centromere and occur-
rence in other patients. The models are fitted on data from glioblastoma and their
corresponding normal samples that were collected as part of The Cancer Genome
Atlas project and hybridized on Agilent 244K arrays. Using the Database alone
CNVs can be correctly identified with about 85% accuracy if the outliers are re-
moved before segmentation and with 72% accuracy if the outliers are included,
and additional variables improve the prediction by about 2-3% and 12%, respec-
tively.
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Abstract
Motivation
Both somatic copy number alterations (CNAs) and germline copy number variants (CNVs)
that are prevalent in healthy individuals can appear as recurrent changes in comparative
genomic hybridization (CGH) analyses of tumors. In order to identify important cancer
genes CNAs and CNVs must be distinguished. Although the Database of Genomic Variants
(Iafrate et al., 2004) contains a list of all known CNVs, there is no standard methodology to
use the database effectively.
Results
We develop a prediction model that distinguishes CNVs from CNAs based on the in-
formation contained in the Database and several other variables, including potential CNV’s
length, height, closeness to a telomere or centromere and occurrence in other patients. The
models are fitted on data from glioblastoma and their corresponding normal samples that
were collected as part of The Cancer Genome Atlas project and hybridized on Agilent 244K
arrays. Using the Database alone CNVs can be correctly identified with about 85% accuracy
if the outliers are removed before segmentation and with 72% accuracy if the outliers are in-
cluded, and additional variables improve the prediction by about 2-3% and 12%, respectively.
Availability: http://www.mskcc.org/mskcc/html/72726.cfm
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1 Introduction
Copy number variants (CNVs) are a recently discovered part of natural genetic variation
in humans. CNVs, also sometimes known as copy number variations or copy number poly-
morphisms, is a collective term for deletions, insertions, duplications and large-scale copy
number variants ranging in size between one kilobase and several megabases (Iafrate et al.,
2004, Freeman et al., 2006 , Redon et al., 2006, Carter, 2007). About 15% of the human
genome, including thousands of genes, may be variable in copy number, and this variation
can be de novo (occurring for the first time in the parent’s germ cell) or inherited from
the parents by healthy individuals (de Smith et al., 2008). Although their significance is
not fully understood, it is likely that CNVs are responsible for a considerable part of phe-
notypic variation. For example, there are established links between CNVs and childhood
onset of schizophrenia (Walsh et al., 2008) and autism (Sebat et al., 2007). It has also been
shown that CNVs can increase the risk of prostate cancer (Liu et al., 2009) and neuroblas-
toma (Diskin et al., 2009). CNVs can contribute to our understanding of complex diseases
through genome-wide association studies together with SNPs and other types of variants
(Beckmann et al., 2007, Ionita-Laza et al., 2009). DNA copy number arrays are the main in-
struments for identifying CNVs. The constant refinement and increasing resolution of these
assays are helping to discover and map many of these variants with high precision.
Before the importance of CNVs was realized it was well known that copy number changes
occur often in cancer. Throughout the manuscript we call such changes copy number alter-
ations (CNAs). CNAs are somatic changes in genomic copy number of any size, up to a whole
chromosome, that occur in the genome of a cancerous cell. These changes often involve im-
portant cancer genes such as tumor suppressor genes and oncogenes. To find important
cancer genes, investigators look for regions that are repeatedly gained or lost in patients
with a particular cancer. CNVs, present in the genome of every cell, are also present in
tumor cells. Thus, when comparative genomic hybridization (CGH) arrays of tumors are
studied both cancer-related CNAs and germline CNVs can appear as unique or recurrent
changes. It would be possible to avoid CNVs using a paired tumor-normal design, with the
normal tissue from the same individual used as a reference. However, if a paired normal
sample is not used or is not available, which is often the case, it is difficult to distinguish
CNAs from CNVs.
To our knowledge, there are currently no statistical methods to identify CNVs in tumor
data. A common practice, recommended, for example, in (Cho et al., 2006), is to evaluate
whether the discovered recurrent regions match known CNVs in the Database of Genomic
Variants (http://projects.tcag.ca/variation) (Iafrate et al., 2004), which we call the
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DGV. It is unclear, however, to what extent the regions should match known CNVs. The
problems associated with this practice are that it might exclude unnecessarily big regions of
the genome, and that regions of exclusion are imprecise due to uncertainty in the endpoints
of the known CNVs (Cho et al., 2006). In addition, the smaller CNVs are less likely to be
included into the DGV since they are detected less frequently in older, low-resolution arrays.
Our goals in this manuscript are twofold. Our first goal is to determine if additional
information can be added to that from the DGV for predicting CNVs in cancer data. Our
second goal is to determine how to optimally use the DGV for this same purpose. We
are looking for any characteristics of CNV regions that are different from cancer-modified
segments and thus can be used to improve prediction. We develop statistical models toward
this goal. These models, in addition to simplifying data analysis, might allow the discovery
of new CNVs from the abundance of available tumor data.
In order to develop our models we have used data from the Agilent 244K array (AG244)
collected on glioblastoma (GBM) patients as part of The Cancer Genome Atlas (TCGA)
project (TCGA-Network, 2008). TCGA data are informative because they include many
paired tumor and normal tissue samples that have been hybridized in the same manner.
Specifically, the tumor samples have been hybridized against a single reference sample, and
the matching normal samples have been hybridized against the same reference sample. Thus
one can identify CNVs in the normal samples as well as distinguish between CNAs and CNVs
in the tumor samples. We investigate whether CNVs and CNAs differ in such variables as
length, height, loss/gain status, overlap with changes in other patients, and other variables.
We divide the patients into training and validation sets, and develop a prediction model that
includes these variables and known literature on CNVs. In addition, TCGA has collected
copy number data on several normal tissue samples, which should contain only CNVs, and
data from tumor samples co-hybridized with the patient’s own normal tissue reference, which
should contain only CNAs. We use these data to further validate our models.
The outline of the paper is as follows. In the next section we describe the data and
introduce the possible variables in the model. Section 3 contains the quantitative results
for the main effects of the predictors, fitted models and their accuracy. The summary and
discussion follow in Section 4.
2 Methods
2.1 Selection of patients
We initially selected the first 206 glioblastoma samples qualified for genomic analyses as part
of TCGA (TCGA-Network, 2008). All of them were hybridized to the AG244 array as well
as other platforms. Here, we limit our analyses to AG244 data collected at the Memorial
Sloan-Kettering Cancer Center. There were 78 patients that satisfied requirements for our
analysis: paired tumor and normal samples that were independently hybridized against
pooled reference. The normal samples varied between blood, skin, and muscle tissue. The
patient data were divided into training and test sets by TCGA batch number in order to
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maintain the heterogeneity that is likely to occur in practice. The training set consisted
of TCGA batches 3, 6, and 7, with 43 patients, while the test set contained batch 5 with
35 patients. The data are of exceptionally high quality and publicly available at (http:
//cancergenome.nih.gov). The details of the sample selection and preparation are given
in (TCGA-Network, 2008).
We originally chose glioblastoma samples to study CNVs because it was the only set of
TCGA patients with a large enough set of matched samples. As it turns out, glioblastoma
is a disease where distinguishing germline mutations might prove to be particularly useful
because tumor induced alterations are often of similar size. Among heterozygous deletions
and amplifications that are present in GBM in at least 10% of patients, as reported previously
(Kotliarov et al., 2006), 40% are focal alterations (1 basepair), and about 90% of the rest of
them are under 3 Mb. Altered regions of similar sizes are reported in the TCGA manuscript
(TCGA-Network, 2008). In fact its authors excluded regions as CNVs if they 1) appeared
to be CNVs in HapMap normals, or 2) appeared in at least 2 independent publications in
DGV, or 3) appeared in the matched normal tissue by manual or automated search. These
exclusion criteria are quite complicated and hard to replicate. We develop a model that
would simplify such an analysis.
2.2 Segmentation analysis
The raw log-ratio data were normalized as described in the supplementary section of the
TCGA manuscript (TCGA-Network, 2008). To identify possible regions of gain and loss,
we segmented the normalized log ratios using two different algorithms: CBS and GLAD.
CBS, or Circular Binary Segmentation (Olshen et al., 2004, Venkatraman and Olshen, 2007)
is a method for segmenting data into regions of equal estimated copy number. It has been
found to have good properties compared to other similar methods (see Willenbrock and
Fridlyand, 2005, Lai et al., 2008), and is included in the Bioconductor package DNAcopy
(www.bioconductor.org). We have used all default parameters, including the significance
level of α = 0.01, except for the minimum gap between the segments was set to be one
standard deviation (undo.sd=1). Users frequently apply a smoothing procedure to remove
outliers from the data prior to segmentation, which can increase power and remove some
smaller gains and losses. On the other hand, smaller regions eliminated by smoothing may
contain CNVs. Therefore, we fit the prediction model on both smoothed and non-smoothed
data.
Alternatively, we estimated intervals of change using the GLAD algorithm (Hupe et al.,
2004, Bioconductor package GLAD) with default parameters. GLAD automatically filters
outliers, analogous to smoothing in CBS. The second method was used to ensure that the
accuracy of the prediction model was not specific to a particular segmentation method.
2.3 Candidate CNVs
The unit of analysis for us is a segment of constant copy number with breakpoints estimated
by one of the segmentation algorithms previously described. We are calling any segment a
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gain or loss that has an average log ratio of at least one median absolute deviation above or
below the array’s median, respectively. Segments inside this range are called normal.
Suppose only tumor data were available. Then long enough gains and losses would not
be confused with CNVs, since CNVs are not longer than several Megabases. Likewise, if a
segment of interest is in the midst of larger gains or losses, it is less important to identify
whether this particular segment was modified in the germline. Therefore, we consider every
segment of gain or loss in the tumor that has length of up to 2.3 Megabases AND is flanked
by at least one normal segment to be a candidate CNV for our classification model. This
definition reproduces the situation where the question of identifying CNVs might arise.
Consecutive gains or consecutive losses were combined if their total length was under 2.3
Mb. The upper threshold for length was motivated by the analysis of true CNVs from the
normal samples. Note that CNVs of greater length than this are reported in the literature;
however, they comprise less than 1% of reported CNVs, and might have characteristics
vastly different from the majority. Although by formal definition CNVs have to be at least
1kb in length as stated by (Redon et al., 2006), we did not use this restriction. Since the
gap between probes was often large and segment lengths were possibly underestimated, we
have included the segments that were shorter than 1Kb, but there were only few of them.
Chromosomes X and Y were excluded from consideration. Any candidates located in the
”physiological” regions shown in Table 6 were also excluded following suggestion by (Scherer
et al., 2007). Physiologic CNVs reflect normal somatic rearrangements that occur in the
immunoglobulin genes and T-cell receptors during their development (Chowdhury and R,
2004, Belessiand et al., 2006, Bemark and MS, 2003).
The matching normal samples were processed and segmented in exactly the same fashion
as the tumor samples. They were used to determine which of the candidate CNVs were true
CNVs. For example, consider Figure 1. All the red segments of gain and loss were found
by smoothed CBS on one chromosome, in addition the blue segments were found if the data
were non-smoothed. The top and bottom panels represent a tumor and the corresponding
normal tissue, respectively. If a gain or loss in a tumor sample exactly matched a gain or loss
in a normal sample, it was considered a true CNV. However, the segmentation algorithm
introduced error in estimation of the breakpoints, so even true CNVs might not exactly
match between the samples. For example, the red segment marked as CNV overlapped with
the matching loss in the normal sample that did not have exactly the same breakpoints.
Furthermore, some segments in the normal sample might not make it to the required
threshold of significance and thus would not be identified by the segmentation algorithm.
In the figure it can be seen that there is an extremely low log ratio (outlier) in a normal
sample corresponding to the last candidate loss (in blue) in the tumor, but it is not extreme
or long enough to be identified by CBS. To make sure that such segments were not missed
we perform a conditional segmentation test for each candidate CNV. In this test we consider
log-ratios in the normal sample corresponding to the candidate segment in a tumor. Suppose
there are k of them. First we calculate their mean µ. Then we randomly draw k values from
the pool of normal sample log-ratios that are located within the candidate and two of its
neighboring segments in the tumor and calculate their mean µ∗; this procedure is repeated
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Figure 1: Example of CNVs and CNAs. One chromosome is shown. Segments in blue are
found only in unsmoothed data. The upper panel contains tumor, while the lower panel is
a matching normal sample. CNVs have either a matching segment in the normal sample
identified by a segmentation algorithm or matching significantly extreme log-ratios identified
by a permutation test. Regions of the normal sample corresponding to CNAs are normal.
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1000 times. If the mean of normal log-ratios corresponding to the candidate segment µ
exceeds the gain/loss threshold and is less extreme than the simulated means µ∗ in less then
(α=0.01 × 100)% of draws, we declare the candidate to be a true CNV.
In summary, each gain or loss candidate CNV is considered a true CNV if it overlaps a
gain or loss in a normal sample identified by a segmentation algorithm, or if the mean of the
corresponding segment in the normal sample is significant by the conditional segmentation
algorithm described above. Otherwise the candidates are considered to be CNAs.
The blue segments in Figure 1 illustrate the trade-offs associated with unsmoothed data.
On one hand, one additional CNA and three CNVs emerge when outliers are included in
the segmentation. On the other hand, some of these new candidates appear as a result of
just one extreme marker. Unless there are array artifacts, it is unlikely that the outliers will
simultaneously occur in two arrays in exactly the same probe, and that gives us confidence
that unsmoothed data can be useful.
True CNV status for each candidate CNV is a response variable in our model. The
predictors for our model are discussed below.
2.4 Database of genomic variants
As mentioned before, previously discovered CNVs are reported in the DGV. This database
has been used before to distinguish CNAs from CNVs (e.g. TCGA-Network [2008]), but
there is no standard quantitative way to make this distinction. In addition, there is some
uncertainty in the breakpoints in the reported CNVs. We propose to quantify the overlap
with the DGV in the following way. For each probe we calculate the total number of reported
variants (unique Variation IDs) that include it. Then, for each candidate CNV its Database
score is defined as average number of these reported variants across all the probes that
comprise it. The resulting number is not usually an integer since most overlapping regions
in the database do not have the same breakpoints. The less a candidate segment overlaps
known CNVs in the DGV, the smaller its Database score.
Alternatively, instead of the number of variants we used the total reported number of
people that had variants overlapping a probe, and this score is called Database score II.
This variable is potentially informative because each variant from the DGV has different
frequency.
The DGV is updated regularly. For our analysis, we used version 7 of the database for
genome build ’hg18’ from March 2009 available at http://projects.tcag.ca/variation/
downloads/variation.hg18.v7.mar.2009.txt.
2.5 Predictors
Detailed definitions of the candidate predictors for our models are presented in Table 1.
These predictors were derived from published results, biological intuition and observations
from studying the data. We divide predictors in three categories: ”demographic”, ”derived”
and ”spatial”.
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”Demographic” variables are the basic characteristics of the candidate segment, such as
its length (in bases), absolute value of segment mean (raw or adjusted by the noise level), gain
or loss status, and difference between segment means of two nearby segments adjusted by the
noise level. We have also included indicator variables for whether a candidate is surrounded
by all normal segments, is within 2 MB of centromere or telomere (Nguyen et al., 2006), or
overlaps any of the known areas of segmental duplication (Sharp et al., 2005).
A ”derived” variable uses information from arrays of other independent patients of the
same study. The most important of these variables records what percent of other tumors
also have a candidate CNV in the same location, and whether it is a gain or a loss. Since the
breakpoints are estimated with error we used two versions of the same predictor, counting
other patients with the segments that either overlap the candidate segment or have at least
one of the breakpoints exactly matching. If other patients have both gains and losses in the
same location, it is likely that this alteration is a CNV. Similarly, a segment that is in an
area where large non-candidate gains (or losses) are frequent is likely to be a CNA.
A ”spatial” variable captures possible association of CNVs with other segments located
on the same chromosome such as percentage of the chromosome that is gained or lost,
existence of nearby candidates and average Database score of the other candidates on the
same chromosome.
2.6 Statistical methods
The response variable in our model is binary, whether a candidate region is a CNV or
CNA, while predictors are either binary, multi-level factors, or continuous. To examine the
univariate relationship between CNV status and the predictors we utilized univariate logistic
regression. This was because it can accommodate variables of all types and provides us with
both significance levels and estimates of the effects. Multivariate logistic regression, however,
was not used since many of the predictors were highly collinear.
Classification and Regression Trees (CART) is a suitable alternative for highly collinear
data (Breiman et al., 1984). CART is a binary tree approach that is based on recursively
splitting on the most predictive variable. CART trees are simple to interpret and have the
ability to uncover complex relationships among correlated predictors. One of the disadvan-
tages of CART is that it is often not optimal in terms of prediction error, partly because it is
greedy (no looking ahead before splitting). Therefore, we have also used random forests (RF)
(Breiman, 2001). RF are a modification of CART that overcome CART’s search difficulties
by building multiple trees based on resampling cases. Classification is based on the “votes”
of each of these trees. These trees further differ from CART trees because only a random set
of predictors is considered at each split. Although this algorithm tends to lead to prediction
accuracy that is superior to CART (Breiman, 2001), the results of RF are more difficult
to visualize and interpret. Therefore, we used both CART and RF. CART and RF were
implemented using the R packages rpart and randomForest, respectively. CART models
were pruned according to the ”1-SE” rule.
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Table 1: Definition of predictors
Variable Definition
Length length of a segment in bases
Segmental duplication 1 if the candidate is overlapping known region of segmen-
tal duplication, 0 otherwise. All regions listed in (Sharp
et al., 2006) that could be successfully translated into
hg18 by hgLiftOver utility (http//genome.ucsc.edu/cgi-
bin/hgLiftOver) were used, see Table 7
Closeness to centromere 1 if the candidate endpoints are within 2Mb of the cen-
tromere, 0 otherwise
Closeness to telomere 1 if the candidate endpoints are within 2Mb of the telom-
ere, 0 otherwise
Sign 1 if the candidate is a gain, -1 if it is a loss
Height absolute value of the candidate segment mean
Relative height absolute value of the candidate segment mean divided
by the median absolute deviation of the array residuals
Break absolute difference between means of two segments sur-
rounding the candidate divided by the median absolute
deviation of the array residuals
Surrounded by Normals 1 if both surrounding intervals are normals, 0 if one of
them is a gain or a loss
Overlap with other patients factor with levels: GG if there is one or more other pa-
tients in the cohort that have overlapping candidates, all
of them are gains; LL if there is one or more other pa-
tients in the cohort that have overlapping candidates, all
of them are losses; GL if there are at least two patients
with overlapping candidates, some of them are gains and
some are losses; None if there is no other patients with
overlapping candidates
Overlap with other patients
- percent
proportion of other patients in the cohort that have over-
lapping candidate
Matching breakpoint in
other patients - percent
proportion of other patients in the cohort that have a
candidate with at least one exactly matching breakpoint
Close to other candidates 1 if there is another candidate CNV within 500kb on the
same chromosome in this patient
Percent of Normal percent of markers on a chromosome where candidate is
located that are not lost or gained
Database score of other can-
didates
average Database score of other candidates on the same
chromosome
Overlap with CNAs number of other patients that have overlapping non-
candidate segment of the same sign as the candidate
(gain or loss)
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3 Results
All the analyses were performed on three data sets: smoothed CBS, GLAD and unsmoothed
CBS. In the training data set they contained 1448, 1624 and 2037 candidate segments,
respectively, and 904 (62%), 744 (46%) and 1448 (71%) of them were considered true CNVs.
The samples in the test set accounted for 1683, 1738 and 2686 candidates and 939 (56%),
846 (49%) and 1727 (64%) true CNVs respectively. There are 638 (510) and 761 (674)
segments in the training and test set respectively that are true CNVs (true CNAs) in both
smoothed CBS and GLAD. The training set contained more patients than the test set but
it contained fewer candidate segments. This can be explained by the fact that training set
had slightly noisier arrays (higher MAD of residuals), and, therefore, there was less power
to detect smaller segments.
3.1 Univariate results
To test association of predictors with true CNV status we pooled the training and test sets.
The results within these sets separately were very similar and are not presented. Table 2
contains both Anova p-values and regression β coefficients.
The smoothed CBS and GLAD had very similar rankings of significant predictors and
their effects. As expected, Database score had the most significant p-value, followed by
Matching breakpoint in other patients - percent in CBS or Overlap with other patients -
percent in GLAD, Length, and Percent of Normal. All other predictors were also significant.
Obviously, overlap with many variants from the DGV was a strong positive predictor of being
a CNV. Segments that were shorter, matched with candidates from many other patients or
overlapped with both gain and loss candidates in other patients were also more likely to
be CNVs. Having other patients with overlapping candidate losses only was also a positive
predictor. As seen from the direction of the main effects in Table 2, CNVs also tended to
have larger absolute values of segment means; were often surrounded by Normal segments;
located on chromosomes with fewer gains and losses, or with other candidates with high
Database score; or located close to a telomere, centromere or segmental duplication. Also,
we saw several clusters of small CNAs right next to each other, so presence of other candidate
segments within 500kb was predictive of CNA.
In unsmoothed CBS the strongest predictor was Overlap with other patients, followed
by the Database score. One possible explanation for this difference is that the small CNVs
are underrepresented in the DGV but are likely to appear in the unsmoothed arrays of
other patients in the cohort. The other notable difference with smoothed segmentation
is that closeness to a centromere, telomere or segmental duplication were not significant,
possibly because longer CNVs tend to be located there. In fact, the interaction term between
length and closeness to centromere (or segmental duplication) was significant in logistic
regression for both smoothed and unsmoothed CBS. As demonstrated by the interaction
effect, segments at these locations and of longer length were even more likely to be CNVs.
Note that these associations are not causal, and the mechanisms by which CNVs occur
and fixate in the population are still to be elucidated.
10
http://biostats.bepress.com/mskccbiostat/paper17
Table 2: Univariate results by logistic regression, training and test sets combined
Smoothed CBS GLAD Unsmoothed CBS
β P β P β P
Height 3.95E-01 1.16E-20 4.88E-01 7.93E-27 8.88E-01 6.47E-117
Relative height 7.14E-02 3.36E-17 9.34E-02 9.75E-26 1.64E-01 7.79E-102
Break -3.43E-01 1.06E-24 -3.39E-01 2.47E-26 -3.42E-01 3.33E-36
Close to other candidates -1.19E+00 2.17E-32 -8.06E-01 6.78E-17 -1.17E+00 1.19E-37
Overlap with CNAs -7.10E-02 1.24E-26 -6.67E-02 6.88E-25 -5.07E-02 9.44E-22
Database score 3.06E-01 4.08E-306 3.06E-01 1.98e-323 2.27E-01 8.60E-186
Database score II 9.79E-03 3.19E-159 9.35E-03 2.16E-167 5.90E-03 5.25E-74
Overlap w. other pts: % 8.89E+00 4.98E-254 8.02E+00 8.64E-276 5.45E+00 1.71E-158
Matching bkpt in other: % 17.31 2.58E-276 13.13 1.11E-246 9.14 3.62E-178
Overlap w. other pts - GG 3.42E-01 3.63E-199 3.37E-01 1.04E-208 -1.70E-01 6.08E-258
LG 2.85E+00 2.85E+00 2.29E+00
LL 1.68E+00 1.73E+00 2.13E+00
Closeness to centromere 8.41E-01 2.55E-09 7.98E-01 2.72E-09 7.15E-02 5.95E-01
Closeness to telomere 4.24E-01 2.15E-04 5.78E-01 2.46E-07 -1.55E-01 1.27E-01
Length -2.46E-06 2.14E-130 -1.78E-06 9.65E-94 -2.65E-06 1.27E-183
Dat. score of other cand. 5.98E-02 6.69E-17 5.45E-02 9.41E-14 5.17E-02 9.02E-11
Percent of Normal 3.40E+00 5.29E-59 2.70E+00 3.35E-50 2.78E+00 1.72E-60
Segmental duplication 6.81E-01 5.71E-11 7.16E-01 1.51E-13 1.79E-01 5.85E-02
Sign -2.74E-01 5.10E-14 -2.62E-01 2.73E-13 -7.05E-01 2.06E-107
Surrounded by Normals 1.30E+00 2.28E-23 1.07E+00 5.02E-23 1.31E+00 7.06E-32
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3.2 Prediction models
We have fitted prediction models using smoothed CBS, GLAD and unsmoothed CBS with
4 different sets of predictors. Accuracy was evaluated on 3 validation sets. The full set
of predictors contained all the variables described in Table 2 except Database score II and
Height that were nearly equivalent to the already included variables Database score and
Relative height.
We first discuss the results based on smoothed CBS. The fitted CART model selected
only five predictors, as is shown in Figure 2. The first split was made on the Database
score: if the probes in the candidate segment were included in the DGV at least 2.45 times
on average, the candidate was predicted to be a CNV. Otherwise, only segments with the
following characteristics were predicted to be CNVs: 1) segments shorter than 30 Kb; or 2)
segments of length longer than 30 Kb that had matching candidate segments in 37% or more
of the other patients. The prediction accuracy of this model, estimated for the smoothed
CBS test set, was 86%, as shown in the Table 3. Table 4 has the numbers of candidate
segments that were correctly and falsely classified. There were 793 true CNVs predicted to
be CNVs, and 654 correctly identified true CNAs. Interestingly, frequency of CNAs falsely
identified as CNVs (182) was much higher than frequency of missed CNVs (54). We believe
CNVs were easier to identify because the DGV contains a lot of information about them.
The other two validation sets we were using were the set of 39 tumors that were hybridized
against self-reference, thus, all its 1780 candidates were true CNAs, and the set of 8 normal
tissue arrays containing 257 true CNVs only. As seen in Table 3, 79% and 90% of these
segments, respectively, were identified correctly. As in the test set, the rate of missed CNVs
was smaller.
The RF model with the same set of predictors increased the accuracy by 1% on the
test set, and by 3-5% on the ’all CNAs’ and ’all CNVs’ sets. Since the best model was a
combination of many trees it is difficult to present it visually; however, relative importance
of each variable measured by Gini index is shown in Table 5. The more influential variables
have higher indices. The ranking of the variables was roughly consistent with univariate
results: the top predictors were Database score, Length,Matching breakpoint in other patients
- percent, Overlap with other patients - percent, Percent of Normal and Relative height.
We have also fitted the CART model with a single variable - Database score. Its only
split was the same as the first split of the full model: segments seen in the DGV on average
2.45 times were predicted to be CNVs. The prediction accuracy of this model was equal to
85%, 88% and 81% on the test, ’all CNAs’ and ’all CNVs’ sets respectively. Therefore, using
all the proposed predictors on the test set in addition to the Database score increased the
accuracy on the test set by 2%.
The fitted CART tree was different in GLAD segmentation, although the first split was
still made on the Database score. As seen in panel (b) of Figure 2, segments were predicted
to be CNVs if 1) they were included in the DGV at least 3 times on average and had relative
absolute mean greater than 1.5; or 2) they were included in the DGV less than 3 times
on average and overlapped with other candidates in at least 38% of other patients of the
cohort. In the RF model for GLAD segmentation, the 6 variables with the highest Gini
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indices (Table 5) were the same as in smoothed CBS segmentation, while having slightly
different ranking. In spite of these differences, the prediction characteristics of models based
on GLAD and smoothed CBS were similar. The RF with all predictors correctly identified
86% of candidates in the test set, 91% of 1861 true CNAs in ’all CNA’ dataset, and 87% of
247 true CNVs in ’all CNVs’ set, while the rates of false CNVs and false CNAs were more
balanced. The model with only Database score had the same first split of Database score
greater or less than 3, and its accuracy on the test set was only 3% smaller than that for the
full model.
Since many of the predictors were highly correlated there could be many classification
trees with similar prediction accuracy, so the difference in models between GLAD and
smoothed CBS might be a result of random variation rather than fundamental segmen-
tation differences. In fact, when we applied the full RF developed on the GLAD segmented
training set to smoothed CBS test set, the prediction accuracy was 87%, which was the
same as the model developed based on smoothed CBS. Similarly, the RF developed on the
smoothed CBS training set resulted in 83% accuracy as assessed in GLAD test set, just 3%
smaller than the RF developed on the GLAD training set.
Prediction modeling based on unsmoothed CBS had several important differences. The
Variable Matching breakpoint in other patients - percent served as a first split in the classifi-
cation tree. If a segment 1) had candidates with matching breakpoints in more than 1.2% of
other patients and was either shorter than 396 Kb or was both longer than 396 Kb and was
included in the DGV on average 4.5 times; or 2) had candidates with matching breakpoints
in less than 1.2% of other patients, was shorter than 22 Kb, or shorter than 77 Kb and
included in the DGV on average 1.3 times, or longer than 77Kb and ncluded in the DGV on
average 3.1 times, then it was predicted to be a CNV. Note that in our training set the first
split is equivalent to having at least one other tumor with exactly matching breakpoint of a
candidate. RF had the same 6 variables with the highest Gini indices as two other segmen-
tation methods, and it correctly predicted 84% of segments in the test set, as well as 77%
of 1785 CNAs and 92% of 464 CNVs in the two other validation sets. Unlike in smoothed
CBS and GLAD, the classification tree that included only Database score showed only 72%
accuracy on the test set, 12% lower than the full model. This model had a much higher false
CNV rate - 66% of all CNAs in the test set and 66% of the CNAs in ’all CNAs’ validation
set were falsely identified as CNVs (see Tables 3, 4). We speculate that unsmoothed CBS
contained smaller intervals that rarely appeared in the DGV, and the Database score was less
informative about them. As a result the model had lower prediction rates on the validation
sets.
While the DGV provided the strongest univariate information, we investigated whether
it was absolutely necessary for predicting CNVs by fitting RF that excluded Database score
and Database score of other candidates. We saw only a modest drop in prediction accuracy
of 0-2%. The most important variables suggested by the Gini index Matching breakpoint in
other patients - percent, Overlap with other patients - percent, Length, Relative height, and
Percent of Normal were the same across all three segmentation methods.
We have also considered models that excluded Overlap with other patients and Overlap
13
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Table 3: Prediction rates: A - test set, B - CGH against self-reference (all CNAs), C - normal
tissue (all CNVs)
CBS smoothed GLAD CBS unsmoothed
A B C A B C A B C
CART-full model 0.86 0.79 0.90 0.83 0.91 0.78 0.80 0.66 0.92
RandomForest - full model 0.87 0.82 0.95 0.86 0.91 0.87 0.84 0.77 0.92
CART- database only 0.85 0.88 0.81 0.83 0.89 0.80 0.72 0.34 0.99
RandomForest - no database 0.85 0.79 0.94 0.86 0.89 0.85 0.82 0.74 0.95
RandomForest - one array 0.85 0.81 0.97 0.84 0.91 0.89 0.83 0.75 0.96
Table 4: Counts of prediction on the test set. (TN, True Negatives, are true CNAs predicted
to be CNAs; FN, False Negatives, are true CNVs predicted to be CNAs; FP, False Positives,
are true CNAs predicted to be CNVs; TP, True Positives, are true CNVs predicted to be
CNVs)
CBS smoothed GLAD CBS unsmoothed
TN FN FP TP TN FN FP TP TN FN FP TP
CART-full model 654 54 182 793 822 145 157 614 613 77 455 1541
RandomForest - full model 659 42 177 805 828 93 151 666 752 124 316 1494
CART- database only 699 120 137 727 804 122 175 637 364 37 704 1581
RandomForest - no database 644 57 192 790 824 91 155 668 686 112 382 1506
RandomForest - one array 647 59 189 788 832 125 147 634 729 120 339 1498
with CNAs, and thus could be applied to a single array. They are presented in the last row
of Tables 3 and 4. There was 1-2% loss of accuracy compared to the full models.
All the analyses were performed in R (http://www.r-project.org/) and the final RF
models are collected in a .RData file, which is available online along with a short manual.
4 Discussion
In this article we introduced a framework for distinguishing germline copy number variants
(CNVs) from cancer-related copy number alterations(CNAs) when analyzing tumor samples
on copy number arrays. To our knowledge, our manuscript is the first attempt to quantify the
overlap of a given copy number abnormality with the database of genomic variants (DGV)
and to suggest a rule for determining CNVs. We have also examined various characteristics
of the altered segments that can be different between CNVs and CNAs.
We considered three segmentation methods to identify candidate CNVs and built CART
and RF prediction models using up to 16 predictors that can be applied to both cohorts
of several independent patients and to single arrays. If the segmentation was done after
removing outliers then the most important predictor was overlap with DGV. If each probe
of a candidate segment overlapped on average with 2.5 - 3 variants listed in the DGV, this
candidate segment was likely to be a CNV. Inclusion of additional variables like Length,
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Table 5: Relative importance of variables in random forest models as measured by Gini index
(higher is more important). ”‘W. DS”’ stands for the model that includes Database score
(DS), ”‘w/o DS”’ stands for the model where it was excluded.
CBS smoothed GLAD CBS unsmoothed
Variable w. DS w/o DS w. DS w/o DS w. DS w/o DS
Relative height 60.33 79.86 81.26 100.96 101.99 119.94
Break 39.98 51.92 48.57 65.75 60.33 72.19
Close to other candidates 8.27 10.83 4.18 6.90 6.19 8.20
Overlap with CNAs 17.21 24.15 17.87 27.10 26.16 34.09
Database score 165.44 206.34 108.89
Overlap w. other pts: % 70.11 107.05 95.23 129.03 74.62 93.67
Matching bkpts in other: % 86.67 108.45 94.02 135.80 116.34 116.83
Overlap with other pts 39.91 59.70 42.18 68.84 86.42 98.28
Closeness to centromere 4.37 5.82 3.74 6.07 4.64 7.17
Closeness to telomere 4.65 6.53 3.31 5.52 6.04 7.11
Length 112.20 133.69 64.26 92.25 170.78 182.46
Lit. score of other cand. 30.23 32.57 44.51
Percent of Normal 64.10 84.05 55.97 76.26 77.18 93.82
Segmental duplication 3.19 7.77 3.48 9.53 5.16 9.34
Sign 7.84 11.01 8.19 12.42 22.59 27.77
Surrounded by Normals 1.87 4.67 5.03 6.66 3.34 5.21
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Figure 2: Fitted CART models
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Relative height, Overlap with other patients in the cohort improved the accuracy by a few
percent. The model developed using one segmentation method can be successfully applied to
another equivalent segmentation (smoothed CBS and GLAD). The advantage of additional
predictors was more pronounced (12% higher accuracy) if the segmentation was performed
on data with no outliers removed. Such data were more likely to contain smaller candidate
segments that are missed in the DGV.
Overall, the prediction accuracy in the test set is around 85% across different segmenta-
tion methods. We have also applied the classification algorithm to validation sets containing
only CNVs (normal samples) or only CNAs (tumor samples with CNVs subtracted as a
reference). The candidate segments were correctly classified in these datasets in 80-95% of
cases, even though our classification model was not developed on these types of samples.
Note that the variable Database score, while being one of the most significant, is based on
the DGV, which has some inaccuracies and repetitions. For each probe it involves the count
of variants listed in the DGV that covered that probe. These variants, however, are not
independent and representation of many of them in the DGV is redundant. For example,
many studies report identical or almost identical variants observed on the same sets of
patients (e.g. HapMap patients), and few variants are listed twice even within the same
study. In addition, variants have been observed in a different number of people and have
different frequencies, although our variable Database score II that utilized these frequencies
did not prove to be superior, probably also due to redundancy in variant reporting. Note
that CNVs discovered by fine scale mapping of DNA from HapMap patients (Perry et al.,
2008) were much smaller, often by more than 50%, than CNVs reported in the DGV based
on previous studies. As the DGV and the frequencies of all known CNVs become more
accurate the prediction model can be improved.
Interestingly, when we have used a previous version of the DGV that contained about half
of the variants listed in March 2009, our prediction model with Database score only was only
about 3% less accurate. That might mean that either the new studies find areas of CNVs
that are known already, or variability of CNVs in the population is so large that expansion
of DGV does not help to predict CNVs in a randomly chosen patient. The Database score
and Overlap with other patients are still the most significant variables across segmentation
methods, and no other characteristic of a single segment is a strong predictor of CNV, so
analyzing genomes from different people and populations is still the best way to increase our
knowledge about CNVs.
Although we have identified true CNVs by matching the candidate segments in tumors
to their corresponding normal samples, our classification is not a gold standard. Due to
segmentation error and possibly imperfect gain/loss calling, some CNVs and CNAs in the
tumors might have been missed. It is also plausible that some true CNVs were missed by
our matching method and classified as true CNAs. However, since we have verified the
prediction framework on several validation sets, we do not expect the error in true CNV
classification to have had a strong impact on the model. We also believe that the fitted
models are not specific to glioblastoma since CNVs should be mostly homogeneous across
patients with different cancers, and the good predictive ability even on the set of normal
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samples supports this claim.
Our models do not depend on the scale of log-ratios since the only important predictor
that depends on them, absolute segment mean, is divided by the median absolute deviation
of noise and as a result, Relative height is scale and noise level invariant. Nevertheless, all
our analyses are done on Agilent 244K arrays, and CNVs might have different characteristics
if they were detected on arrays of different resolution or different platforms. We believe that
the model will be as efficient on arrays that have similar or worse quality and resolution,
since they likely identify CNVs that are similar to or a subset of what can be found by the
Agilent 244K platform.
The Agilent 244K array, like all non-SNP arrays, measures total copy number rather than
allele-specific copy number. That is, it cannot separately estimate the two parental copy
number contributions. This could lead to occassional error in our analysis. For instance, if
there were CNVs on both alleles, and if there were a copy neutral LOH event (one parental
copy number doubles while the other disappears) that was larger than the LOH event, it is
possible that we would interpret this event as a CNA (which would be correct), a CNV, or
a normal region. The interpretation would depend on the allelic copy numbers of both the
normal and tumor samples. This problem, however, is due to the limitation of the array, not
to our algorithm.
Many studies that have the goal of identifying cancer genes deliberately exclude CNVs
prior to analysis (e.g. TCGA-Network, 2008). One way to do this using our algorithm would
be to segment the original data and apply the appropriate RF model. The probes within
predicted CNVs in at least one, or, conservatively, several patients could be excluded, and
the reduced data set could be segmented again for the final analyses. Alternatively, since
predictions are obtained for all segments that are located in areas of suspected recurrent
gain or loss, a region might be discarded if some or many of the matching candidates are
predicted to be CNVs.
It is also interesting to study CNVs in cancer patients. For example, there is evidence
that CNVs may contribute to chromosome breakage (Camps et al., 2008) and to cancer
risk (Liu et al., 2009, Diskin et al., 2009). There are abundant studies of copy number
on cancer patients that are publically available. For any of these studies the data can be
segmented and all the candidate segments can be classified as CNVs or CNAs. The presence
of CNVs as identified by the proposed method can be correlated with recurrent CNAs or
clinical characteristics. Therefore, the classification model that we developed may facilitate
the study of the associations between CNVs and cancer predisposition or progression.
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Table 6: Excluded physiological regions
Chromosome Band Start End Length (Mb)
14 14q32 88900000 106368585 17.47
2 2p11 83700000 93300000 9.60
22 22q11 11800000 24300000 12.5
14 14q11 15600000 23600000 8.0
7 7p15-14 19500000 43300000 23.8
7 7q35 142800000 147500000 4.7
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Table 7: Regions of segmental duplication (hg18)
Chr Start End Chr Start End
1 16570674 21529374 11 58554872 58637894
1 39644292 39911443 11 67234307 71193473
1 47099424 47334837 11 89115225 89470331
1 103844412 104029488 12 9327471 9492133
1 146602113 146661002 12 62209686 62432514
1 193443399 193652009 13 18671435 24453912
1 219038488 224480378 13 51669868 52085380
3 125158410 127197788 13 63188926 63316389
3 196868577 198872158 14 23493142 23575846
4 69859408 70069921 14 105115790 105315245
4 119878950 120719095 15 18458590 30687000
4 145064435 145427952 15 32458295 32663190
5 288807 1670110 15 41638428 41829002
5 98754230 99764829 15 42896927 43162682
6 26775196 26910469 15 70698861 76014417
6 167549682 167776550 15 80369380 83616515
7 5706510 6645758 15 98136837 100152120
7 29465820 34905805 16 11926088 30254369
7 39589900 56270708 16 68535000 73147662
7 63915737 64811465 17 2900905 3103469
7 65881831 76336440 17 25951597 27440083
7 101575559 101918082 17 40928985 42496803
7 142735699 143009437 17 55005024 55434745
7 143321690 143512024 17 55438128 57730605
7 149024431 153302009 18 10594202 12221380
8 2167585 2331389 19 12357800 12416157
8 6933975 12586975 19 22351818 22654242
8 145259369 145464193 19 41455485 42488459
9 33513535 38611353 19 48141176 48323040
9 83653430 85697014 19 48390180 48493611
9 87757240 87984665 19 48532243 48593758
9 90061677 90604904 19 53098556 55818494
9 94148624 96869327 20 45887213 45968382
10 15014850 15108910 21 14268806 14363850
10 42509728 44964465 22 15380222 23404567
10 80921582 82008421 22 23947411 24252773
10 88972008 89250343 22 41226611 41302954
10 135125032 135282940
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